Skip to content
Home/Companies/Biotech/Vivoryon
Vivoryon

Vivoryon

Biotech·France·Exited 2014·Held 5yr
Entry
2009
Hold
5yr
Exit
2014

Who owns Vivoryon?

Vivoryon was owned by Andera Partners through BioDiscovery 3 (2009 vintage) from 2009 to 2014, exited via IPO.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 3 · 2009 · VC

Key facts

HQFrance
SectorBiotech
Websitewww.vivoryon.com
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2014

More from BioDiscovery 3

Other portfolio companies in the same fund.

Cellnovo
Exited 2015
MedTechFrance· 2011
GenKyoTex
Exited 2014
BiotechFrance· 2011
Sapiens
Sapiens
Exited 2013
MedTechFrance· 2011
to
Covagen
Exited 2014
BiotechFrance· 2010
to
Parvulus Medical
Exited
MedTechFrance· 2010
Poxel
Poxel
Active
BiotechFrance· 2010

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Vivoryon

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Vivoryon?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Vivoryon.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue